|
Patent landscape, scope, and claims: |
Scope and Claims Analysis: US Patent 5,474,535 (Erectile Dysfunction Intraurethral Solid Dosage Forms)
US Patent 5,474,535 claims intraurethral delivery devices that carry solid doses at ambient temperature of erectile-dysfunction (ED) therapeutics. The core claim architecture combines (1) an urethra-sized shaft with a structural limitation that prevents complete insertion (Claim 1) and/or supports (2) a cavity at a blunted/distal end with (3) solid dosing that can dissolve, absorb, melt, or bioerode in the urethra. The landscape pivots on the combination of (a) delivery mechanics (partial insertion stop, distal cavity, displacement) and (b) formulation state (solid at ambient temperature, low dose mass) tied to ED indications.
What Do the Independent Claims Cover?
Claim 1: Partial-insertion shaft with distal cavity delivery of a low-mass solid dose
Claim 1 is the broadest “system” claim. It requires, in combination:
- A shaft sized to be received in the male urethra:
- Proximal end and blunted distal end.
- Means to prevent complete insertion of the shaft into the urethra via a limitation located on the proximal end.
- A dose of a therapeutic composition carried in the shaft prior to insertion.
- The therapeutic composition is for ED and has specific physical/biopharmaceutical attributes:
- Dose weighs < about 100 mg
- Solid at ambient temperature
- Capable of being dissolved, absorbed, melted or bioeroded in the urethra.
In claim-scope terms, Claim 1 is not limited to a particular drug class. It is constrained by ED indication and dose physical state.
Key scope hooks
- “Solid at ambient temperature” is a claim-limiting functional attribute of the dose.
- “Capable of being dissolved, absorbed, melted or bioeroded in the urethra” further narrows to materials that undergo transformation in the urethral environment.
- “Prevent complete insertion” is a device design limitation that can be implemented by a stop surface, flange, or equivalent structure at the proximal end, as long as it performs the stated function.
Claim 18: Insert + piston displacement with a dose cavity
Claim 18 is a second independent device platform claim, anchored on mechanics of a dose receiving cavity and active piston displacement.
Required elements:
- Insert including:
- Shaft with proximal and distal ends sized for male urethra.
- A bore within the shaft.
- Piston slidably received in the bore:
- Moves between:
- First position: piston forms a dose receiving cavity proximate to the distal end.
- Second position: piston displaces the dose from the cavity into the urethra.
- The dose is received in the cavity and:
- is solid at ambient temperature
- is capable of being dissolved, absorbed, melted or bioeroded in the urethra.
Key differences vs Claim 1
- Claim 1 relies on a shaft with blunted distal end and proximal insertion stop while carrying dose prior to insertion.
- Claim 18 requires a two-position piston that forms/clears a cavity. It is structurally more specific about internal mechanics.
Dependent Claims: What Additional Narrowing Exists?
Device geometry and positioning
- Claim 2: Adds a cavity containing the therapeutic composition at the blunted distal end of the shaft.
- Claim 3: Adds means for displacing composition from the cavity into the urethra.
- Claim 4: Limits placement location:
- deposit between the proximal portion of the fossa navicularis and the distal position of the pendulous urethra.
- Claim 6: Constrains shaft length:
Dose mass constraints
- Claim 5: dose ≤ 50 mg.
- Claim 20: dose in Claim 18 is ≤ 50 mg.
- Claim 11: provides explicit microgram/milligram ranges for specific agent classes (see below).
- Claim 1 baseline:
These mass limits are an important competitive boundary. They are not “preferred ranges” in the text you provided; they are claim constraints.
Formulation includes permeation enhancers
- Claim 7: composition comprises a urethral permeation enhancer.
Indication-linked agent selection
Claim set draws agent logic through ED subtype labeling:
-
Impotence / ED:
- Claim 8: dysfunction is impotence; agent comprises one or more vasodilators.
- Claim 9: vasodilators selected from a broad list including:
- nitrates
- long and short acting alpha-blockers
- calcium blockers
- ergot alkaloids
- chlorpromazine, haloperidol
- yohimbine
- natural and synthetic vasoactive prostaglandins and analogs
- vasoactive intestinal peptides
- dopamine agonists
- opioid antagonists
- mixtures
- Claim 10: agent comprises an alpha-blocker and a prostaglandin.
- Claim 11: specific ranges:
- 10–2000 μg vasoactive prostaglandin
- 1–50 mg papaverine
- 1–10 mg phentolamine
- 50–2000 μg prazosin
- 50–2000 μg doxazosin
- 50–2000 μg terazosin
- mixtures
- Claim 12: further comprises polyethylene glycol; agent is alpha-blocker + prostaglandin.
- Claim 13: agent consists essentially of alprostadil and prazosin.
-
Priapism:
- Claim 14: dysfunction is priapism; agent comprises one or more vasoconstrictors.
- Claim 16: priapism; agent selected from alpha-agonists and beta-blockers.
-
Peyronie’s syndrome:
- Claim 15: dysfunction is Peyronie’s syndrome; agent is selected from
- steroidal and nonsteroidal anti-inflammatory agents and mixtures.
Polyethylene glycol inclusion
- Claim 17: therapeutic composition further comprises polyethylene glycol.
Insert mechanical closure and piston attachment
For Claim 18 platform:
- Claim 19: defines that the insert shaft is closed at distal end to form a flexible peripheral wall, and piston is attached to the interior surface of that wall; when piston is in the first position the flexible peripheral wall forms the cavity enclosing the dose.
Claim Scope Maps: What a Potential Infringer Would Need to Match
Hard requirements that tend to be difficult to design around
- Intraurethral dosage form
- Dose is carried in a shaft sized for the urethra, positioned to deposit within defined urethral regions (Claim 4).
- Solid at ambient temperature
- Transformability in urethra
- dissolve, absorb, melt, or bioerode.
- Low dose mass
- <100 mg baseline; often further narrowed to ≤50 mg in dependent claims.
- Delivery mechanics
- Claim 1: structural prevention of complete insertion plus blunted distal end, and (in Claim 2/3) cavity/displacement.
- Claim 18: bore + slidable piston with first cavity-forming position and second discharge position.
Soft requirements that still matter
- “Means” clauses in Claim 1 and Claim 3 can be implemented with multiple mechanical variants, but they are still claim-limiting because they must perform the stated function.
- “Capable of” transformation in urethra can be met by a range of solid forms if the material can dissolve/melt/erode, but it remains a functional boundary.
Where the Patent Likely Sits in the ED/Urethral Delivery Landscape
Based on the claims’ specificity, US 5,474,535 is best read as a form factor and delivery method patent rather than a single-molecule patent:
- It targets local urethral deposition of solid ED agents.
- It combines device structure (urethral shaft, distal cavity, stop feature, piston displacement mechanics) with formulation state (solid at ambient temperature, low mass).
- It provides explicit dosing ranges for key ED actives and combinations:
- prostaglandin (10–2000 μg)
- alpha-blockers (prazosin/doxazosin/terazosin 50–2000 μg)
- phentolamine (1–10 mg) and papaverine (1–50 mg)
- and combo logic (alpha-blocker + prostaglandin, polyethylene glycol use; alprostadil + prazosin “consists essentially of”).
This structure indicates the patent landscape around it likely splits into:
- Device-only variants that change geometry/piston mechanics while attempting to avoid the claimed insertion stop and/or cavity/displacement features; and/or
- Formulation-only variants that alter the drug list, dose mass, or solid characteristics; and/or
- Form-factor variants that shift from intraurethral solid deposits to other ED administration routes (to avoid the urethra deposit requirement).
Freedom-to-Operate (FTO) Lens: Key Avoidance Axes
Axis 1: Dose mass
- Staying above 100 mg (Claim 1) or above 50 mg (Claim 5/20) can fall outside these claim constraints.
- Commercial ED therapies often use different dosing formats; this claim set is tightly bound to small mass doses in a solid form.
Axis 2: Physical state at ambient temperature
- Changing the formulation so it is not “solid at ambient temperature” can avoid a claim limitation, even if delivery is intraurethral and drug is otherwise similar.
Axis 3: Delivery mechanism architecture
- Claim 1’s “means to prevent complete insertion” and Claim 18’s piston/bore structure are distinct. A competing device that does not:
- stop complete insertion (Claim 1), or
- includes piston displacement cavity mechanics (Claim 18),
can reduce risk depending on the exact claim asserted.
Axis 4: Composition composition constraints
- Claim 8 to 13 and the priapism/Peyronie’s dependent sets constrain which agents map to which ED indication.
- If an accused product treats ED using a different agent set not encompassed by the “selected from the group consisting of” list (Claims 9, 11, 15, 16) or outside the ranges (Claim 11), it may avoid those narrower dependent claims, but Claim 1/18 could still be asserted if the therapeutic composition still meets the broad functional and physical limitations.
Practical Claim-Value Ranking (From Broadest-to-Narrowest Based on Provided Text)
- Claim 1 (broadest device + solid dose + low mass + urethral insertion stop concept)
- Claim 18 (broad device platform using insert + piston displacement, still tied to solid dose and low mass constraints via dependents)
- Claim 2 and 3 (add cavity + displacement specifics)
- Claim 4 and 6 (add urethral deposition position and shaft length)
- Claim 5 and 20 (add tighter dose mass limit)
- Claim 7, 17 (adds permeation enhancer and polyethylene glycol)
- Claims 8-13 (imposes vasodilator/alpha-blocker/prostaglandin relationships and numeric ranges)
- Claims 14-16 (priapsism/Peyronie’s indication mapping and vasoconstrictor/anti-inflammatory selection)
- Claim 19 (adds specific flexible peripheral wall and piston attachment features)
What the Claims Imply About Competitive Activity
Likely design targets for competitors
- Substitute alternative delivery structures:
- for example, non-piston mechanics or different cavity-clearing strategies that do not meet the “means for displacing” or piston placement/operation claims.
- Change dose presentation:
- non-solid at ambient temperature or dose outside the defined mg ranges.
- Reframe agent selection:
- avoid matching the explicitly enumerated vasodilator families or the “consists essentially of” composition (alprostadil + prazosin) if a competitor’s formulation lands at a similar dose.
- Remove urethral positioning specificity:
- if deposition location is not within the claimed fossa navicularis to pendulous urethra region (Claim 4), the dependent positioning claim may not fit.
Where risk concentrates
- Any product that matches:
- urethral shaft with distal cavity carrying a solid ED dose,
- ≤50 mg,
- dissolvable/meltable/bioerodible solid,
- and a compatible mechanical delivery feature
is aligned with the heart of Claim 1/2/3/5 (and Claim 18 variants).
Key Takeaways
- US 5,474,535 is built around intraurethral delivery of low-mass solid ED doses, with transformation in the urethra as a claim-limiting functional attribute.
- The two independent claim pillars are (i) a distal cavity shaft with a proximal insertion stop (Claim 1) and (ii) an insert-bore-piston system that forms and then clears a cavity (Claim 18).
- Dependent claims narrow via urethral positioning, shaft length, dose mass (often ≤50 mg), permeation enhancers and polyethylene glycol, and specific agent classes and dosing ranges tied to ED, priapism, or Peyronie’s syndrome.
- Competitive design-around risk is highest when products match solid-at-ambient + low mg + intraurethral placement + cavity/displacement mechanics.
FAQs
1) Does US 5,474,535 claim a specific erectile dysfunction drug?
Not in the independent claims as provided. Claims 1 and 18 require a “therapeutic agent” for erectile dysfunction, but they are not restricted to a single molecule. Narrower dependent claims enumerate vasodilators and dosing ranges.
2) What is the main limitation about the dose material?
The dose is solid at ambient temperature and is capable of being dissolved, absorbed, melted or bioeroded in the urethra.
3) What dose mass limits appear in the claims?
- Claim 1: dose weighs less than about 100 mg
- Claim 5: dose weighs not more than 50 mg
- Claim 20: dose in Claim 18 is not more than 50 mg
- Claim 11 provides explicit drug-range quantities, including microgram and milligram windows for listed agents.
4) How do Claims 1 and 18 differ mechanically?
Claim 1 centers on a shaft with a blunted distal end and means to prevent complete insertion via the proximal end. Claim 18 requires a bore plus a slidable piston that moves between a cavity-forming position and a discharge position.
5) Which dependent claims are most likely to be relevant in infringement arguments?
The highest-friction dependents are typically those that add objective structural and quantitative constraints: Claims 2-4, 6, 5/20, 7/17, and 8-13 (for ED agent class and numeric ranges).
References
[1] United States Patent No. 5,474,535 (claims as provided in prompt).
More… ↓
⤷ Start Trial
|
